BioSpace News Archive

Innate Pharma SA announced updated preliminary clinical data from an ongoing Phase I dose escalation and expansion study evaluating the safety and efficacy of the combination of monalizumab.

Macrogen, Inc. announced on June 5 that it has established Macrogen Asia Pacific Pte. Ltd., a subsidiary in Singapore.

The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced results from a Phase 2 study that were published in The Lancet demonstrating positive results for TREMFYA® (guselkumab).

Johnson & Johnson named James Allison, Ph.D., of University of Texas MD Anderson Cancer Center, winner of the 2018 Dr. Paul Janssen Award for Biomedical Research, and launched several new programs as part of our Champions of Science platform to fuel public engagement, support and trust in science.

Rodo Medical, Inc. announces FDA 510(k) clearance of the Rodo Smilekey, an induction remover device for use with the Rodo Abutment System.

DSG, Inc. will be exhibiting at the 54th DIA Global Annual Meeting and Conference at booth 1707.

June 4, 2018 13:00 UTC Opdivo (nivolumab) 3 mg/kg Demonstrates Sustained, Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) 10 mg/kg for Broad Range of Patients with Resected Stage III or IV Melanoma Opdivo is the only I-O therapy to demonstrate superiority versus an active control in this patient population Updated results represent longest follow-up of any PD-1 inhibitor in the adjuvant melanoma se

Seattle Genetics, Inc. (Nasdaq:SGEN) today highlighted data from the phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy in newly diagnosed stage III or IV classical Hodgkin lymphoma (HL) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

Mr. Coleman will be responsible for sourcing and leading financing assignments for biopharma and medtech companies on a global basis

Turning food into a force to fight AIDS, EAT (RED) SAVE LIVES 2018 has returned.